Formestane: Difference between revisions

Jump to navigation Jump to search
m (Protected "Formestane": Protecting pages from unwanted edits ([edit=sysop] (indefinite) [move=sysop] (indefinite)))
 
No edit summary
 
(2 intermediate revisions by 2 users not shown)
Line 1: Line 1:
{{Editor Help}}
{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 437193284
| IUPAC_name = (8''R'',9''S'',10''R'',13''S'',14''S'')-4-hydroxy-10,13-dimethyl-2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-cyclopenta[''a'']phenanthrene-3,17-dione
| image = Formestane1.png


<!--Clinical data-->
| tradename = 
| Drugs.com = {{drugs.com|international|formestane}}
| pregnancy_category = 
| legal_status = 
| routes_of_administration = 


{{Drugbox|
<!--Pharmacokinetic data-->
|IUPAC_name = (8''R'',9''S'',10''R'',13''S'',14''S'')-4-hydroxy-10,13-dimethyl-<br>2,6,7,8,9,11,12,14,15,16-decahydro-1''H''-<br>cyclopenta[a]phenanthrene-3,17-dione
| bioavailability = 
| image= Formestane.png
| metabolism = 
| CAS_number=566-48-3
| excretion =
| ATC_prefix=L02
 
| ATC_suffix=BG02  
<!--Identifiers-->
| ATC_supplemental=
| CAS_number_Ref = {{cascite|correct|??}}
| PubChem=11273
| CAS_number = 566-48-3
| DrugBank=
| ATC_prefix = L02
| C = 19 | H = 26 | O = 3  
| ATC_suffix = BG02
| PubChem = 11273
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10799
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = PUB9T8T355
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D07260
| ChEBI_Ref = {{ebicite|changed|EBI}}
| ChEBI = 75172
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 132530
 
<!--Chemical data-->
| C=19 | H=26 | O=3  
| molecular_weight = 302.408 g/mol
| molecular_weight = 302.408 g/mol
| bioavailability=  
| smiles = O=C4C(/O)=C3/CC[C@@H]2[C@H](CC[C@@]1(C(=O)CC[C@H]12)C)[C@@]3(C)CC4
| metabolism =  
| InChI = 1/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
| elimination_half-life=
| InChIKey = OSVMTWJCGUFAOD-KZQROQTABI
| excretion =
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| pregnancy_category =  
| StdInChI = 1S/C19H26O3/c1-18-10-8-15(20)17(22)14(18)4-3-11-12-5-6-16(21)19(12,2)9-7-13(11)18/h11-13,22H,3-10H2,1-2H3/t11-,12-,13-,18+,19-/m0/s1
| legal_status =  
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| routes_of_administration=  
| StdInChIKey = OSVMTWJCGUFAOD-KZQROQTASA-N
| synonyms = <small>4-hydroxyandrost-4-ene-3,17-dione</small>
}}
}}
'''Formestane''' belongs to a class of drugs known as [[aromatase inhibitors]].  It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.  It is available as an intramuscular depot injection (Lentaron).
__NOTOC__
{{SI}}
{{CMG}}
==Overview==
'''Formestane''' ('''Lentaron''') is a type I, steroidal [[aromatase inhibitor]].  It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women.  It is available as an intramuscular depot injection.


Formestane is often used to suppress [[estrogen]] production from [[anabolic steroids]] or [[prohormones]].
Formestane is often used to suppress [[estrogen]] production from [[anabolic steroids]] or [[prohormones]].  It also acts as a prohormone to [[4-hydroxytestosterone]], an active steroid which displays weak [[androgenic]] activity in addition to acting as a mild aromatase inhibitor.


Formestane has poor oral bioavailability and as such is no longer popular as many orally available aromatase inhibitors have been developed.
Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.


It is available as a supplement for bodybuilders in transdermal formulations.
It is selective.


==References==
{{Reflist|2}}


{{Sex hormones}}
[[Category:Aromatase inhibitors]]
[[Category:Aromatase inhibitors]]
[[Category:Endocrinology]]
[[Category:Drug]]
{{WikiDoc Help Menu}}
{{WikiDoc Sources}}

Latest revision as of 14:37, 13 April 2015

Formestane
Clinical data
Synonyms4-hydroxyandrost-4-ene-3,17-dione
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
ChEBI
ChEMBL
E number{{#property:P628}}
ECHA InfoCard{{#property:P2566}}Lua error in Module:EditAtWikidata at line 36: attempt to index field 'wikibase' (a nil value).
Chemical and physical data
FormulaC19H26O3
Molar mass302.408 g/mol
3D model (JSmol)
 ☒N☑Y (what is this?)  (verify)

WikiDoc Resources for Formestane

Articles

Most recent articles on Formestane

Most cited articles on Formestane

Review articles on Formestane

Articles on Formestane in N Eng J Med, Lancet, BMJ

Media

Powerpoint slides on Formestane

Images of Formestane

Photos of Formestane

Podcasts & MP3s on Formestane

Videos on Formestane

Evidence Based Medicine

Cochrane Collaboration on Formestane

Bandolier on Formestane

TRIP on Formestane

Clinical Trials

Ongoing Trials on Formestane at Clinical Trials.gov

Trial results on Formestane

Clinical Trials on Formestane at Google

Guidelines / Policies / Govt

US National Guidelines Clearinghouse on Formestane

NICE Guidance on Formestane

NHS PRODIGY Guidance

FDA on Formestane

CDC on Formestane

Books

Books on Formestane

News

Formestane in the news

Be alerted to news on Formestane

News trends on Formestane

Commentary

Blogs on Formestane

Definitions

Definitions of Formestane

Patient Resources / Community

Patient resources on Formestane

Discussion groups on Formestane

Patient Handouts on Formestane

Directions to Hospitals Treating Formestane

Risk calculators and risk factors for Formestane

Healthcare Provider Resources

Symptoms of Formestane

Causes & Risk Factors for Formestane

Diagnostic studies for Formestane

Treatment of Formestane

Continuing Medical Education (CME)

CME Programs on Formestane

International

Formestane en Espanol

Formestane en Francais

Business

Formestane in the Marketplace

Patents on Formestane

Experimental / Informatics

List of terms related to Formestane

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]

Overview

Formestane (Lentaron) is a type I, steroidal aromatase inhibitor. It is used in the treatment of estrogen-receptor positive breast cancer in post-menopausal women. It is available as an intramuscular depot injection.

Formestane is often used to suppress estrogen production from anabolic steroids or prohormones. It also acts as a prohormone to 4-hydroxytestosterone, an active steroid which displays weak androgenic activity in addition to acting as a mild aromatase inhibitor.

Formestane has poor oral bioavailability and as such is no longer popular as many orally active aromatase inhibitors have been identified.

It is selective.

References